Disclaimer: You are now leaving www.beiresources.org and are going to a website that is not operated by BEI Resources. We are not responsible for the content or availability of linked sites.
ABOUT THIRD PARTY LINKS ON OUR SITE: BEI Resources offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links, you will leave the BEI Resources website and will be redirected to another site. These sites are not under the control of BEI Resources. BEI Resources is not responsible for the content of linked third party websites. We are neither an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information. Please read third party privacy and security policies closely as these may be different than BEI Resources policies. If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.
The Malaria Research and Reference Reagent Resource Center (MR4) has provided quality controlled malaria reagents, protocols and technical support for the international research community since 1998. Supported by the National Institute of Allergy and Infectious Diseases (NIAID) and now part of the NIAID BEI Resources, MR4 acquires, authenticates, preserves and distributes parasites, mosquito vectors and associated biological and molecular reagents. MR4 materials are provided at no cost to registered researchers (additional shipping and handling charges may apply).
Artemisinin resistant in vitro culture-adapted clinical isolates from Didier Menard at the Institut Pasteur du Cambodge have been deposited in MR4 for use in the ring-stage survival assay (RSA) and other screening applications. Six culture isolates, with DHA treated RSA values ranging from 0.1% to >68%, are now available. Genomic DNAs from these isolates are set for release in the near future.
Looking for Non-Mosquito Vectors?
BEI Resources houses a new Vector Resources collection including non-malaria mosquitoes and other arthropod vectors of infectious disease.
Plasmodium falciparum Senegal and Tanzania Field Isolates released New Plasmodium falciparum field isolates obtained from villages near Dakar, Senegal are from patient populations that were recently exposed to multiple, changing drug regimens due to the emergence of clinical resistance to traditional drugs. The parasites exhibit diverse genetic barcodes and antimalarial drug sensitivity profiles (Park et al., PNAS, 109: 13052–13057, 2012). MRA-1169, Plasmodium falciparum 02000708 Tanzania, a clinical isolate from Morogoro, has also become available in the catalog. Click here to view isolates.
The NIAID MR4 program has been your go-to resource for malaria repository reagents for nearly 12 years. As part of the integration and consolidation of NIAID specalized programs of biological materials, MR4 is now part of NIAID centralized research material repository, BEI Resources. Click here to learn more about BEI Resources.
Since 2012, BEI Resources efforts to acquire, authenticate and measure the in vitro susceptibility of drug-resistant malarial strains from different endemic countries have amassed a catalog of over 100 strains with unique susceptibility profiles to a variety of compounds. This data assists registrants and prospective users in making judicious data-driven isolate requests to meet their research needs.
An overview of these strains, complete with in vitro drug and parasite survival assay results, was presented by the BEI Resources team at the 33rd Molecular Parasitology Meeting (MPM) in Woods Hole, Massachusetts, in September 2022. MPM drew researchers focusing on parasitic pathogens that significantly impact global human and livestock health, such as Cryptosporidium, Leishmania, Trypanosoma, the malaria-causing Plasmodium, and many others.
MPM Poster_06Sep2022